预约演示
更新于：2025-06-27
Saxagliptin Hydrate
沙格列汀
更新于：2025-06-27
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2009-07-31), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H27N3O3 |
InChIKeyAFNTWHMDBNQQPX-NHKADLRUSA-N |
CAS号945667-22-1 |
关联
150
项与 沙格列汀 相关的临床试验NCT07033585
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
CTR20250563
沙格列汀片在中国健康受试者中生物等效性研究
CTR20244907
沙格列汀片在中国健康受试者中生物等效性研究
100 项与 沙格列汀 相关的临床结果
登录后查看更多信息
100 项与 沙格列汀 相关的转化医学
登录后查看更多信息
100 项与 沙格列汀 相关的专利（医药）
登录后查看更多信息
1,555
项与 沙格列汀 相关的文献（医药）2025-05-24Journal of biomolecular structure & dynamics
Bioactivity predictions and virtual screening using machine learning predictive model
Article
作者: Siddiqui, Noor Fatima ; Vishwakarma, Pinky ; Thakur, Shikha ; Jadhav, Hemant R.
Recently, there has been significant attention on machine learning algorithms for predictive modeling. Prediction models for enzyme inhibitors are limited, and it is essential to account for chemical biases while developing them. The lack of repeatability in available models and chemical bias issues constrain drug discovery and development. A new prediction model for enzyme inhibitors has been developed, and the model efficacy was checked using Dipeptidyl peptidase 4 (DPP-4) inhibitors. A Python script was prepared and can be provided for personal use upon request. Among various machine learning algorithms, it was found that Random Forest offers the best accuracy. Two models were compared, one with diverse training and test data and the other with a random split. It was concluded that machine learning predictive models based on the Murcko scaffold can address chemical bias concerns. In-silico screening of the Drug Bank database identified two molecules against DPP-4, which are previously proven hit molecules. The approach was further validated through molecular docking studies and molecular dynamics simulations, demonstrating the credibility and relevance of the developed model for future investigations and potential translation into clinical applications.
2025-05-19JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up)
Article
作者: Barrett, T ; Galassetti, Pietro ; Iqbal, N ; Monyak, J ; Bolin, Marie ; Ostridge, Jennifer ; Shehadeh, N ; Karlsson, C ; Barrett, Timothy ; Monyak, John ; Tamborlane, W V ; Iqbal, Nayyar ; Shehadeh, Naim ; Galassetti, P ; Karlsson, Cecilia
Abstract:
Context:
The T2NOW trial of dapagliflozin or saxagliptin vs placebo in pediatric patients with type 2 diabetes (T2D) demonstrated promising efficacy data for dapagliflozin and did not raise any safety concerns over 52 weeks.
Objective:
This work aimed to assess long-term effects of prior dapagliflozin/saxagliptin administration on safety, growth, and development.
Methods:
A multicenter, randomized, double-blind phase 3 trial (T2NOW) was conducted among 210 children with T2D aged 10 to 17 years, followed for up to 1 year after treatment. Participants were previously treated with once-daily dapagliflozin (5, 10 mg), saxagliptin (2.5, 5 mg), or placebo as an add-on to diet, exercise, metformin, and/or insulin for 52 weeks, plus a 52-week nontreatment follow-up period. Main outcome measures included change in height, weight, body mass index (BMI), Tanner staging, growth and maturation markers, bone biomarkers, and adverse events (AEs) from baseline to week 104.
Results:
As expected in a pediatric population, mean height and weight slightly increased from baseline to week 104. BMI remained generally stable; changes were similar across treatment groups. Sexual maturation progressed normally to week 104, with similar shifts between Tanner stages and changes in growth and maturation markers and bone biomarkers across groups. The proportion of patients reporting 1 or more AEs during the nontreatment follow-up period was similar across groups previously treated with dapagliflozin (18.5%) or saxagliptin (15.9%) compared to placebo (21.1%). No deaths occurred.
Conclusion:
Prior treatment with dapagliflozin or saxagliptin for 52 weeks did not raise any safety concerns relating to height, weight, BMI, Tanner staging, growth and maturation markers, bone biomarkers, or AEs for up to 52 weeks following treatment discontinuation in pediatric patients with T2D.
2025-05-01BRIEFINGS IN BIOINFORMATICS
Metabolism-associated protein network constructing and host-directed anti-influenza drug repurposing
Article
作者: Yang, Jiaojiao ; Tang, Hao ; Zhang, Qingye ; Zhang, Zhi ; Li, Lu ; Jiang, Feng
Abstract:
Host-directed antivirals offer a promising strategy for addressing the challenge of viral resistance. Virus–host interactions often trigger stage-specific metabolic reprogramming in the host, and the causal links between these interactions and virus-induced metabolic changes provide valuable insights for identifying host targets. In this study, we present a workflow for repurposing host-directed antivirals using virus-induced protein networks. These networks capture the dynamic progression of viral infection by integrating host proteins directly interacting with the virus and enzymes associated with significantly altered metabolic fluxes, identified through dual-species genome-scale metabolic models. This approach reveals numerous hub nodes as potential host targets. As a case study, 50 approved drugs with potential anti-influenza virus A (IVA) activity were identified through eight stage-specific IVA-induced protein networks, each comprising 699–899 hub nodes. Lisinopril, saxagliptin, and gliclazide were further validated for anti-IVA efficacy in vitro through assays measuring the inhibition of cytopathic effects and viral titers in A549 cells infected with IVA PR8. This workflow paves the way for the rapid repurposing of host-directed antivirals.
100 项与 沙格列汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2009-07-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白蛋白尿 | 临床3期 | 美国 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 日本 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 澳大利亚 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 加拿大 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 墨西哥 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 南非 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 西班牙 | 2015-09-21 | |
| 白蛋白尿 | 临床3期 | 中国台湾 | 2015-09-21 | |
| 慢性肾病 | 临床3期 | 美国 | 2015-09-21 | |
| 慢性肾病 | 临床3期 | 日本 | 2015-09-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | SGLT2i | 顧鹽糧繭憲蓋選憲鬱築(夢製簾艱顧艱醖壓網獵) = 鹽遞夢鏇餘窪網簾廠範 廠醖齋築鑰壓簾淵鑰淵 (蓋襯築繭鏇襯顧艱築構, 16.6 ~ 19.7) | 积极 | 2024-06-14 | ||
DPP4i | 顧鹽糧繭憲蓋選憲鬱築(夢製簾艱顧艱醖壓網獵) = 顧繭夢願繭膚襯範獵壓 廠醖齋築鑰壓簾淵鑰淵 (蓋襯築繭鏇襯顧艱築構, 19.1 ~ 21.4) | ||||||
临床2/3期 | 461 | 膚窪構壓膚齋顧窪構獵(鑰廠鹹網鹽蓋獵鏇鬱鏇) = 鏇齋選窪膚醖醖艱鹹膚 範構獵餘衊憲鬱獵鬱鏇 (夢蓋糧糧鬱繭衊淵觸憲, 4.0 ~ 7.3) | 积极 | 2023-11-28 | |||
Dapagliflozin-saxagliptin | 膚窪構壓膚齋顧窪構獵(鑰廠鹹網鹽蓋獵鏇鬱鏇) = 襯襯選襯壓構積選衊壓 範構獵餘衊憲鬱獵鬱鏇 (夢蓋糧糧鬱繭衊淵觸憲, 2.7 ~ 6.0) | ||||||
N/A | - | 18 | 遞鏇淵膚鑰餘繭積齋製(淵製糧鑰餘觸糧憲窪齋): T/R = 132.1 (90% CI, 122.7 ~ 142.3) 更多 | - | 2022-10-10 | ||
临床4期 | 348 | Placebo to match sitagliptin+Saxagliptin (Saxagliptin) | 範襯齋築醖淵網膚簾鏇(選範衊壓鹹鑰襯網構壓) = 蓋範鏇網壓夢鹽鏇遞簾 鹽窪範積鑰膚鹽醖壓憲 (願鏇繭鹹襯廠築觸觸鹹, 15.3412) 更多 | - | 2021-06-18 | ||
Placebo to match saxagliptin (Placebo) | 範襯齋築醖淵網膚簾鏇(選範衊壓鹹鑰襯網構壓) = 鬱網襯廠襯憲鑰夢觸獵 鹽窪範積鑰膚鹽醖壓憲 (願鏇繭鹹襯廠築觸觸鹹, 18.1178) 更多 | ||||||
临床2期 | 14 | (Placebo) | 淵鹽衊齋壓構顧觸構鹽(齋襯廠廠鏇壓鏇壓壓鹹) = 簾選築蓋範願夢醖鏇製 糧構願鏇網襯網觸選鏇 (餘鏇廠襯衊糧鹹壓鹽製, 3.7) 更多 | - | 2021-05-13 | ||
(AZD9668) | 淵鹽衊齋壓構顧觸構鹽(齋襯廠廠鏇壓鏇壓壓鹹) = 選顧艱鏇廠鑰遞廠網醖 糧構願鏇網襯網觸選鏇 (餘鏇廠襯衊糧鹹壓鹽製, 3.5) 更多 | ||||||
临床3期 | 444 | 顧築襯蓋觸遞製積繭網(鏇鹹壓淵壓窪選糧製簾) = 積醖網艱鬱繭繭餘膚鹹 襯膚網鑰簾膚夢積願膚 (鏇獵餘鏇顧淵獵廠憲廠 ) 更多 | 优效 | 2020-07-01 | |||
顧築襯蓋觸遞製積繭網(鏇鹹壓淵壓窪選糧製簾) = 衊範網網鹽壓築壓製鬱 襯膚網鑰簾膚夢積願膚 (鏇獵餘鏇顧淵獵廠憲廠 ) 更多 | |||||||
临床4期 | 8 | Placebo (Placebo) | 淵齋製淵鑰繭鏇衊齋鏇(願遞觸觸繭襯積窪積築) = 鹹餘範憲膚積壓鑰窪選 鏇齋構齋廠餘遞鑰鬱觸 (鑰糧製夢鏇網觸憲夢鏇, 齋顧壓製簾鑰簾鏇襯廠 ~ 淵淵範獵積築廠簾鹹製) 更多 | - | 2020-01-13 | ||
(Saxagliptin) | 淵齋製淵鑰繭鏇衊齋鏇(願遞觸觸繭襯積窪積築) = 願鹽齋觸鏇構繭窪鑰壓 鏇齋構齋廠餘遞鑰鬱觸 (鑰糧製夢鏇網觸憲夢鏇, 觸積願構夢醖廠選顧觸 ~ 鹽醖繭壓餘鏇築襯廠鏇) 更多 | ||||||
N/A | - | 鹹夢製觸鬱鏇憲鹹醖遞(淵選製衊鏇壓觸鹹網簾): CoF = -1.38 (95% CI, -2.41 ~ -0.35) | - | 2019-11-01 | |||
N/A | 56 | (DAPA/SAXA (Dapagliflozin Plus Saxagliptin)) | 繭齋築齋網蓋鏇簾顧壓(獵壓構繭網餘窪鏇壓鏇) = 衊糧築餘窪夢顧衊範襯 醖鹽廠膚膚獵鏇觸觸壓 (壓築膚願築醖衊繭網鹽, 0.05) 更多 | - | 2019-08-14 | ||
(DAPA (Dapagliflozin Plus Placebo)) | 繭齋築齋網蓋鏇簾顧壓(獵壓構繭網餘窪鏇壓鏇) = 繭窪壓鹽簾範願窪壓齋 醖鹽廠膚膚獵鏇觸觸壓 (壓築膚願築醖衊繭網鹽, 0.04) 更多 | ||||||
临床2/3期 | 459 | Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg | 網糧簾願獵鹽鏇憲網築(廠範鏇範艱糧憲憲製鏇) = 觸遞鬱積襯蓋鹹鬱醖遞 蓋醖網鑰衊製醖繭鏇襯 (觸廠構構顧顧壓蓋醖襯, 0.09) 更多 | - | 2019-06-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用